Search Result

Results for "

aciduria

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) ATP Synthase (2) Bacterial (1) CGRP Receptor (2) Endogenous Metabolite (21) Ferroportin (1) Fungal (1) GABA Receptor (1) GCGR (5) GLP Receptor (5) Isotope-Labeled Compounds (6) mTOR (2) Oxytocin Receptor (1) PD-1/PD-L1 (2) Phospholipase (1) PKC (2) Reactive Oxygen Species (2) Vasopressin Receptor (2)
By Research Areas:	Cancer (6) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (5) Metabolic Disease (30) Neurological Disease (5)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113005

Glutarylcarnitine	Endogenous Metabolite	Metabolic Disease
Glutarylcarnitine is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes.

HY-113005A

Glutarylcarnitine lithium	Endogenous Metabolite	Metabolic Disease
Glutarylcarnitine lithium is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes .

HY-113377A

L-Glyceric acid sodium	Endogenous Metabolite	Metabolic Disease
L-Glyceric acid sodium is a mainly urinary metabolite accumulating in rare inherited metabolic disease L-glyceric aciduria. L-Glyceric acid sodium can be used to diagnose primary hyperoxaluria type 2 (PH2). L-Glyceric acid sodium excretion to distinguish PH1 from PH2 .

HY-113005S

Glutarylcarnitine-d9 chloride	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Glutarylcarnitine-d₉ (chloride) is the deuterium labeled Glutarylcarnitine chloride. Glutarylcarnitine is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes.

HY-113377

L-Glyceric acid	Endogenous Metabolite	Metabolic Disease
L-Glyceric acid is a mainly urinary metabolite accumulating in rare inherited metabolic disease L-glyceric aciduria. L-Glyceric acid can be used to diagnose primary hyperoxaluria type 2 (PH2). L-Glyceric acid excretion to distinguish PH1 from PH2 .

HY-W018035

DL-Glyceric Acid Glyceric Acid (20% in Water,ca.2 mol/L)	Endogenous Metabolite	Metabolic Disease
DL-Glyceric Acid is a compound that is secreted excessively in the urine by patients suffering from D-glyceric aciduria.

HY-W015874

2-Hydroxy-2-methylbutanoic acid	Endogenous Metabolite	Metabolic Disease
2-Hydroxy-2-methylbutanoic acid, an unusual metabolite, is associated with 2-hydroxyglutaric aciduria and maple syrup urine disease.

HY-113406

Hexanoylcarnitine	Others	Inflammation/Immunology
Hexanoylcarnitine exists in human urine and plasma. Hexanoylcarnitine can be used as a plasma detection indicator in patients with methylmalonic aciduria, propionic acidemia, and medium-chain acyl-CoA dehydrogenase deficiency .

HY-W008820

Glutaric acid	Endogenous Metabolite	Metabolic Disease
Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I .

HY-W016813

trans-Aconitic acid	Endogenous Metabolite	Others
trans-Aconitic acid is present in normal human urine, and it has been suggested that is present in larger amounts with Reye's syndrome and organic aciduria. trans-Aconitic acid is a substrate of enzyme trans-aconitate 2-methyltransferase.

HY-N5134

5'-Guanylic acid 1 Publications Verification 5'-GMP; 5'-guanosine monophosphate	Endogenous Metabolite	Metabolic Disease
5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-W008820S

Glutaric acid-d6	Endogenous Metabolite	Metabolic Disease
Glutaric acid-d₆ is the deuterium labeled Glutaric acid. Glutaric acid is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].

HY-W008820S1

Glutaric acid-d4	Endogenous Metabolite	Metabolic Disease
Glutaric acid-d₄ is the deuterium labeled Glutaric acid. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].

HY-W008820S2

Glutaric acid-d2	Endogenous Metabolite	Metabolic Disease
Glutaric acid-d₂ is the deuterium labeled Glutaric acid. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].

HY-139427

3-Methylglutaconic acid β-Methylglutaconic acid	GABA Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
3-Methylglutaconic acid is the major metabolites accumulating in 3-Methylglutaconic aciduria (MGTA). 3-Methylglutaconic acid can induce lipid oxidative damage and protein oxidative. 3-Methylglutaconic acid decreases the non-enzymatic antioxidant defenses in cerebral cortex supernatants to elicit oxidative stress in the cerebral cortex. 3-Methylglutaconic acid can be used for brain damage disease research .

HY-P10218A

MANS peptide TFA	PKC	Inflammation/Immunology Cancer
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P10218

MANS peptide	PKC	Inflammation/Immunology Cancer
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-N5134S1

5'-Guanylic acid-13C10 dilithium 5'-GMP-¹³C₁₀ dilithium; 5'-guanosine monophosphate-¹³C₁₀ dilithium	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
5'-Guanylic acid- ¹³C₁₀ (5'-GMP- ¹³C₁₀ dilithium; 5'-guanosine monophosphate- ¹³C₁₀) dilithium is ¹³C-labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-N5134S2

5'-Guanylic acid-15N5 dilithium 5'-GMP-¹⁵N₅ dilithium; 5'-guanosine monophosphate-¹⁵N₅ dilithium	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
5'-Guanylic acid- ¹⁵N₅ (5'-GMP- ¹⁵N₅ dilithium; 5'-guanosine monophosphate- ¹⁵N₅) dilithium is ¹⁵N labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-N5134S3

5'-Guanylic acid-d12 dilithium 5'-GMP-d₁₂ dilithium; 5'-guanosine monophosphate-d₁₂ dilithium	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
5'-Guanylic acid-d₁₂ (5'-GMP-d₁₂ dilithium; 5'-guanosine monophosphate-d₁₂) dilithium is deuterium labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-113038

D-α-Hydroxyglutaric acid (R)-2-Hydroxyglutarate; (R)-2-Hydroxyglutaric acid; (R)-2-Hydroxypentanedioic acid	Reactive Oxygen Species ATP Synthase mTOR Endogenous Metabolite	Neurological Disease Inflammation/Immunology Cancer
D-α-Hydroxyglutaric acid ((R)-2-Hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a K_i of 10.87 mM. D-α-Hydroxyglutaric acid increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid binds and inhibits ATP synthase and inhibits mTOR signaling .

HY-100542

D-α-Hydroxyglutaric acid disodium 3 Publications Verification Disodium (R)-2-hydroxyglutarate	Reactive Oxygen Species ATP Synthase mTOR Endogenous Metabolite	Neurological Disease Inflammation/Immunology Cancer
D-α-Hydroxyglutaric acid disodium (Disodium (R)-2-hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid disodium is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a K_i of 10.87 mM. D-α-Hydroxyglutaric acid disodium increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid disodium binds and inhibits ATP synthase and inhibits mTOR signaling .

HY-N5134S5

5'-Guanylic acid-13C10,15N5 dilithium 5'-GMP-¹³C₁₀,¹⁵N₅ dilithium; 5'-guanosine monophosphate-¹³C₁₀,¹⁵N₅ dilithium	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
5'-Guanylic acid- ¹³C₁₀, ¹⁵N₅ (5'-GMP- ¹³C₁₀, ¹⁵N₅ dilithium; 5'-guanosine monophosphate- ¹³C₁₀, ¹⁵N₅) dilithium is ¹³C and ¹⁵N-labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-113410

3-Methylglutaric acid	Endogenous Metabolite	Metabolic Disease
3-Methylglutaric acid, a leucine metabolite, is a conspicuous C6 dicarboxylic organic acid classically associated with two distinct leucine pathway enzyme deficiencies, 3-hydroxy-3-methylglutaryl CoA lyase (HMGCL) and 3-methylglutaconyl CoA hydratase (AUH) .

HY-P10200

CP7-FP13-2	Bacterial	Infection
CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .

HY-N5134S4

5'-Guanylic acid-15N5,d12 dilithium 5'-GMP-¹⁵N₅,d₁₂ dilithium; 5'-guanosine monophosphate-¹⁵N₅,d₁₂ dilithium	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
5'-Guanylic acid- ¹⁵N₅,d₁₂ (5'-GMP- ¹⁵N₅,d₁₂ dilithium; 5'-guanosine monophosphate- ¹⁵N₅,d₁₂) dilithium is deuterium and ¹⁵N labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-P0041A

F992 TFA

Vasopressin Receptor Neurological Disease

F992 TFA is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .

F992 TFA	Vasopressin Receptor	Neurological Disease
F992 TFA is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .

HY-P3462

Cagrilintide	CGRP Receptor	Metabolic Disease
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .

HY-P3462A

Cagrilintide acetate	CGRP Receptor	Metabolic Disease
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .

HY-P5161A

FC382K10W15 TFA

GCGR Metabolic Disease

FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research .

FC382K10W15 TFA	GCGR	Metabolic Disease
FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research .

HY-P10271

RG7697	GLP Receptor	Metabolic Disease
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC₅₀ of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin, which has the ability to continuously improve glycemic control. Meanwhile, ZP3022 can effectively increase the mass of β-cells, promote β-cell proliferation, and enhance the average islet mass. ZP3022 can be used in research for anti-diabetic treatments .

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P4146A

Survodutide TFA BI 456906 TFA	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-113560

Plipastatin B1

Antibiotic Fungal Phospholipase Infection

Plipastatin B1 is a lipopeptide that serves as an inhibitor of phospholipase A₂ (PLA2) and possesses antifungal activity .

Plipastatin B1	Antibiotic Fungal Phospholipase	Infection
Plipastatin B1 is a lipopeptide that serves as an inhibitor of phospholipase A₂ (PLA2) and possesses antifungal activity .

HY-P1162

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin SKF 100273	Vasopressin Receptor	Metabolic Disease
(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin (SKF 100273) is a vasopressin V1 receptor selective antagonist .

HY-P10031

SAR441255	GLP Receptor GCGR	Metabolic Disease
SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys .

HY-P10031A

SAR441255 TFA	GLP Receptor	Metabolic Disease
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 TFA displays high potency with balanced activation of all three target receptors.?SAR441255 TFA shows positive acute glucoregulatory effectss in diabetic obese monkeys .

HY-P4895

(d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin	Oxytocin Receptor	Neurological Disease
(d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is an oxytocin receptor antagonist. (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin can be used for the research of neurological disease .

HY-P10272

Rusfertide PTG-300	Ferroportin	Others
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .

Cat. No.	Product Name	Target	Research Area

HY-P10218A

MANS peptide TFA	PKC	Inflammation/Immunology Cancer
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P0041A

F992 TFA

Vasopressin Receptor Neurological Disease

F992 TFA is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .

F992 TFA	Vasopressin Receptor	Neurological Disease
F992 TFA is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .

HY-P10218

MANS peptide	PKC	Inflammation/Immunology Cancer
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P4837

Ac-Lys-D-Ala-D-lactic acid	Peptides	Others
Ac-Lys-D-Ala-D-lactic acid is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .

HY-P10200

CP7-FP13-2	Bacterial	Infection
CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .

HY-P3462

Cagrilintide	CGRP Receptor	Metabolic Disease
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .

HY-P3462A

Cagrilintide acetate	CGRP Receptor	Metabolic Disease
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .

HY-P5161A

FC382K10W15 TFA

GCGR Metabolic Disease

FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research .
HY-P5161

FC382K10W15

Peptides Metabolic Disease

FC382K10W15 is a glucagon derivative useful for diabetes research .

HY-P10271

RG7697	GLP Receptor	Metabolic Disease
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC₅₀ of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin, which has the ability to continuously improve glycemic control. Meanwhile, ZP3022 can effectively increase the mass of β-cells, promote β-cell proliferation, and enhance the average islet mass. ZP3022 can be used in research for anti-diabetic treatments .

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P4146A

Survodutide TFA BI 456906 TFA	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-113560

Plipastatin B1

Antibiotic Fungal Phospholipase Infection

Plipastatin B1 is a lipopeptide that serves as an inhibitor of phospholipase A₂ (PLA2) and possesses antifungal activity .

HY-P1162

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin SKF 100273	Vasopressin Receptor	Metabolic Disease
(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin (SKF 100273) is a vasopressin V1 receptor selective antagonist .

HY-P10031

SAR441255	GLP Receptor GCGR	Metabolic Disease
SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys .

HY-P10031A

SAR441255 TFA	GLP Receptor	Metabolic Disease
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 TFA displays high potency with balanced activation of all three target receptors.?SAR441255 TFA shows positive acute glucoregulatory effectss in diabetic obese monkeys .

HY-P4895

(d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin	Oxytocin Receptor	Neurological Disease
(d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is an oxytocin receptor antagonist. (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin can be used for the research of neurological disease .

HY-P10272

Rusfertide PTG-300	Ferroportin	Others
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113005

Glutarylcarnitine	Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Glutarylcarnitine is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes.

HY-113005A

Glutarylcarnitine lithium	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Glutarylcarnitine lithium is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes .

HY-113377A

L-Glyceric acid sodium	Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
L-Glyceric acid sodium is a mainly urinary metabolite accumulating in rare inherited metabolic disease L-glyceric aciduria. L-Glyceric acid sodium can be used to diagnose primary hyperoxaluria type 2 (PH2). L-Glyceric acid sodium excretion to distinguish PH1 from PH2 .

HY-W018035

DL-Glyceric Acid Glyceric Acid (20% in Water,ca.2 mol/L)	Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
DL-Glyceric Acid is a compound that is secreted excessively in the urine by patients suffering from D-glyceric aciduria.

HY-113377

L-Glyceric acid	Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
L-Glyceric acid is a mainly urinary metabolite accumulating in rare inherited metabolic disease L-glyceric aciduria. L-Glyceric acid can be used to diagnose primary hyperoxaluria type 2 (PH2). L-Glyceric acid excretion to distinguish PH1 from PH2 .

HY-W015874

2-Hydroxy-2-methylbutanoic acid	Classification of Application Fields Other disease Ketones, Aldehydes, Acids Source classification Disease markers Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
2-Hydroxy-2-methylbutanoic acid, an unusual metabolite, is associated with 2-hydroxyglutaric aciduria and maple syrup urine disease.

HY-113406

Hexanoylcarnitine	Structural Classification Natural Products Classification of Application Fields Animals Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Others
Hexanoylcarnitine exists in human urine and plasma. Hexanoylcarnitine can be used as a plasma detection indicator in patients with methylmalonic aciduria, propionic acidemia, and medium-chain acyl-CoA dehydrogenase deficiency .

HY-W008820

Glutaric acid	Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Disease markers Metabolic Disease Endocrine diseases Nervous System Disorder Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I .

HY-W016813

trans-Aconitic acid	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Human Gut Microbiota Metabolites Microorganisms Immune System Disorder Ketones, Aldehydes, Acids Other Diseases Disease markers Nervous System Disorder Disease Research Fields Cancer	Endogenous Metabolite
trans-Aconitic acid is present in normal human urine, and it has been suggested that is present in larger amounts with Reye's syndrome and organic aciduria. trans-Aconitic acid is a substrate of enzyme trans-aconitate 2-methyltransferase.

HY-N5134

5'-Guanylic acid 1 Publications Verification 5'-GMP; 5'-guanosine monophosphate	Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-113038

D-α-Hydroxyglutaric acid (R)-2-Hydroxyglutarate; (R)-2-Hydroxyglutaric acid; (R)-2-Hydroxypentanedioic acid	Classification of Application Fields Neurological Disease Anti-aging Source classification Endocrine diseases Endogenous metabolite Immune System Disorder Ketones, Aldehydes, Acids Disease markers Nervous System Disorder Disease Research Fields Inflammation/Immunology Cancer	Reactive Oxygen Species ATP Synthase mTOR Endogenous Metabolite
D-α-Hydroxyglutaric acid ((R)-2-Hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a K_i of 10.87 mM. D-α-Hydroxyglutaric acid increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid binds and inhibits ATP synthase and inhibits mTOR signaling .

HY-100542

D-α-Hydroxyglutaric acid disodium 3 Publications Verification Disodium (R)-2-hydroxyglutarate	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Cancer	Reactive Oxygen Species ATP Synthase mTOR Endogenous Metabolite
D-α-Hydroxyglutaric acid disodium (Disodium (R)-2-hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid disodium is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a K_i of 10.87 mM. D-α-Hydroxyglutaric acid disodium increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid disodium binds and inhibits ATP synthase and inhibits mTOR signaling .

HY-113410

3-Methylglutaric acid	Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Disease markers Metabolic Disease Endocrine diseases Nervous System Disorder Endogenous metabolite Disease Research Fields Cardiovascular System Disorder	Endogenous Metabolite
3-Methylglutaric acid, a leucine metabolite, is a conspicuous C6 dicarboxylic organic acid classically associated with two distinct leucine pathway enzyme deficiencies, 3-hydroxy-3-methylglutaryl CoA lyase (HMGCL) and 3-methylglutaconyl CoA hydratase (AUH) .

Cat. No.	Product Name	Chemical Structure

HY-113005S

Glutarylcarnitine-d9 chloride
Glutarylcarnitine-d₉ (chloride) is the deuterium labeled Glutarylcarnitine chloride. Glutarylcarnitine is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes.

HY-W008820S

Glutaric acid-d6
Glutaric acid-d₆ is the deuterium labeled Glutaric acid. Glutaric acid is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].

HY-W008820S1

Glutaric acid-d4
Glutaric acid-d₄ is the deuterium labeled Glutaric acid. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].

HY-W008820S2

Glutaric acid-d2
Glutaric acid-d₂ is the deuterium labeled Glutaric acid. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].

HY-N5134S1

5'-Guanylic acid-13C10 dilithium
5'-Guanylic acid- ¹³C₁₀ (5'-GMP- ¹³C₁₀ dilithium; 5'-guanosine monophosphate- ¹³C₁₀) dilithium is ¹³C-labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-N5134S2

5'-Guanylic acid-15N5 dilithium
5'-Guanylic acid- ¹⁵N₅ (5'-GMP- ¹⁵N₅ dilithium; 5'-guanosine monophosphate- ¹⁵N₅) dilithium is ¹⁵N labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-N5134S3

5'-Guanylic acid-d12 dilithium
5'-Guanylic acid-d₁₂ (5'-GMP-d₁₂ dilithium; 5'-guanosine monophosphate-d₁₂) dilithium is deuterium labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-N5134S5

5'-Guanylic acid-13C10,15N5 dilithium

5'-Guanylic acid- ¹³C₁₀, ¹⁵N₅ (5'-GMP- ¹³C₁₀, ¹⁵N₅ dilithium; 5'-guanosine monophosphate- ¹³C₁₀, ¹⁵N₅) dilithium is ¹³C and ¹⁵N-labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-N5134S4

5'-Guanylic acid-15N5,d12 dilithium

5'-Guanylic acid- ¹⁵N₅,d₁₂ (5'-GMP- ¹⁵N₅,d₁₂ dilithium; 5'-guanosine monophosphate- ¹⁵N₅,d₁₂) dilithium is deuterium and ¹⁵N labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

aciduria

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products